It wasn’t always this way. Leveraging AI in drug development is not only thanks to growing access to semiconductor chips, but ...

This suggests there may be a potential compiler bug related to handling complex macro expansions, which could involve structured bindings (a C++20 feature) and recursive macro logic.

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. 10 stocks we like better than ...

Palantir, Tempus and Recursion are racing to reshape drug discovery with AI and data-driven platforms. Investors are watching closely as these disruptors challenge Big Pharma’s traditional R&D with ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has seen significant share price volatility in 2025, dropping 27% year-to-date and trading over 55% below its 52-week high of $12. Despite this underperformance ...

Rallybio Corporation RLYB agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals ...

Not sure if tracking macros is right for you? This guide breaks down how to do it in a simple, low-stress way that helps you stay consistent and avoid burnout. If you’re weighing the pros and cons of ...